Skip to main content

Peanut Allergy clinical trials at UCSF
2 in progress, 1 open to new patients

  • PALISADE Follow-on Study (ARC004)

    open to eligible people ages 4–55

    The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.

    San Francisco, California and other locations

  • Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.

    San Francisco, California and other locations